In addition to the previously discovered common loss-of-function variant CYP3A5*3 allele (rs776746), the Deterioration of Kidney Allograft Function (DeKAF) Trial identified two CYP3A5 variants, rs10264272 and rs41303343, and one CYP3A4 variant, rs35599367, that explain additional portions of variance observed in dose-adjusted tacrolimus (TAC) through blood concentrations for African American (AA) and European ancestry (EA) kidney transplant recipients, respectively (Dai et al., 2006; Jacobson et al., 2011; Oetting et al., 2016; Oetting et al., 2018). The gene discussed is CYP3A5; the disease is medical procedure.